Fig. 4: Transcriptional changes and pathway analysis of cells from teplizumab treated patients in the TN10 trial who are EBV-seropositive vs EBV-seronegative.

A Heatmap showing the Z score of the pathways with significant differences in the CD8⁺ and CD4⁺ T cells subclusters at the baseline (n = 6 EBV-seropositive and n = 8 EBV-seronegative). The pathways were determined by IPA analysis based on the DEGs between EBV positive and EBV negative in the placebo and teplizumab group. Blue and red scale denote grades of prediction of downregulation or upregulation of the pathways based on the Z score. B Heatmap showing the Z score of the pathways with significant differences (in the CD8⁺, CD4⁺ T cells at 3 months and 18 moths (n = 4 EBV-seropositive, n = 3 EBV-seronegative)). The pathways were determined by IPA analysis and based on the DEGs between EBV positive and EBV negative in the teplizumab group at each timepoint after filtering out the genes that showed changes at the baseline and pathways that change in the placebo group at the same timepoints. Blue and red scale denote grades of prediction of downregulation or upregulation of the pathways based on the Z score. C Volcano plot visualization of the DEGs in EBV positive vs negative related to the mTOR signaling pathway in the CD8 effector cluster at 18 months, and (D) Volcano plot visualization of the DEGs in EBV positive vs negative related to the NFκB in the Treg cluster at 3 months. E Heatmap showing the Z score of the significant pathways in the B cells cluster at 3 months and 18 months. CM: central memory, EM: effector memory.